In this study we evaluate the potential MGMT’s role in control of therapeutic, clinically relevant, cell cycle regulators involved in breast cancer oncogenesis (CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1). This evidence concerns the gene KIF20A and breast cancer.